Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
4.010
-0.080 (-1.96%)
At close: Aug 21, 2026, 4:00 PM EDT
4.020
+0.010 (0.25%)
After-hours: Aug 21, 2026, 7:30 PM EDT
Adagene Revenue
Adagene had revenue of $1.62M in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to $9.29M, up 8,902.38% year-over-year. In the year 2025, Adagene had annual revenue of $7.67M with 7,332.76% growth.
Revenue (ttm)
$9.29M
Revenue Growth
+8,902.38%
P/S Ratio
29.05
Revenue / Employee
$72,584
Employees
128
Market Cap
269.92M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | 7.57M | 7,332.76% |
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Invivyd | 58.37M |
| AC Immune | 21.67M |
| Lineage Cell Therapeutics | 13.08M |
| Surrozen | 11.51M |
| Whitehawk Therapeutics | 7.15M |
| Entrada Therapeutics | 4.69M |
| Camp4 Therapeutics | 4.22M |
ADAG News
- 2 days ago - Adagene to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 weeks ago - Adagene Slides: Corporate presentation - Filings
- 3 months ago - Adagene Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 3 months ago - Adagene Slides: Investor presentation - Filings
- 3 months ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR - TheFly
- 4 months ago - Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types - GlobeNewsWire